Significantly, RAS mutations, usually in KRAS and NRAS, are also frequent events in myeloid malignancies, and have been detected in 3% to 40% of myelodysplastic syndrome (MDS) and AML [5–7]. The gene discussed is KRAS; the disease is acute myeloid leukemia.